▲ 0.88%
prev close
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-31 | ROIVRoivant Sciences Ltd. - Common Shares | Sell | $1,001 - $15,000 | 333d ago | — | |
| 2025-10-30 | ROIVRoivant Sciences Ltd. - Common Shares | Sell | $1,001 - $15,000 | 333d ago | — |
2025-10-31
Lisa McClain
ROIV
Amount
$1,001 - $15,000
Filed
333d ago
2025-10-30
Lisa McClain
ROIV
Amount
$1,001 - $15,000
Filed
333d ago
Recent News
Powered by Polygon.io
Company News for Sep 9, 2026
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-31 · Sale
$1,001 - $15,000
Lisa McClain
2025-10-30 · Sale
$1,001 - $15,000